share_log

Stifel Downgrades Silk Road Medical to Hold, Raises Price Target to $27.5

Benzinga ·  Jul 17 17:18

Stifel analyst Rick Wise downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and raises the price target from $23 to $27.5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment